Weill Cornell Genitourinary Cancer Program

01/19/2026

Hear more from Dr. Jim Hu about a new posterior approach to nerve-sparing prostatectomy for patients via Urology Times:

Jim C. Hu, MD, MPH, discusses the functional advantages of a posterior approach to endopelvic neurovascular total sparing (PATENTS) robotic-assisted radical prostatectomy.

12/19/2025

Watch Dr. Scott Tagawa talk to GU Oncology Now about the PSMAddition trial which evaluated intensifying treatment earlier in patients with :

Dr. Tagawa provides the latest clinical update from PSMAddition and relevancy for community and academic practitioners alike.

11/26/2025

At , Dr. Scott Tagawa spoke with OncLive about the rapidly changing treatment landscape for and :

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

11/24/2025

Learn more about the differences between androgen receptor pathway inhibitors (ARPIs) and androgen deprivation therapy (ADT) combinations for metastatic hormone-sensitive from Dr. Cora Sternberg:

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

11/15/2025

Hear Dr. Scott Tagawa’s interview with Oncology Learning Network about the results he presented at and the potential future of the therapy:

Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with metastatic hormone-sensitive prostate cancer.

11/12/2025

Dr. Cora Sternberg spoke with Targeted Oncology about the evolution of combination therapies for metastatic hormone-sensitive :

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

11/08/2025

At , Dr. Scott Tagawa spoke with ESMO - European Society for Medical Oncology as part of the Breaking Science video series about his Presidential Symposium presentation:

11/06/2025

Listen to Dr. Cora Sternberg discuss treatment options for hormone-sensitive and targeting the androgen-sensitive pathway on this via Future Oncology Taylor Francis:

This podcast examines how hormone-sensitive prostate cancer (HSPC) is treated, specifically looking at therapies that target the androgen-sensitive pathway. Identification of patients and the clini...

11/05/2025

Continuing coverage from : Learn more about the results Dr. Scott Tagawa presented on a lutetium Lu 177 vipivotide tetraxetan combination for a subset of patients:

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

11/03/2025

ICYMI: Dr. Scott Tagawa presented results at evaluating the ability of a radioligand therapy to slow hormone-sensitive progression

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of....

10/30/2025

Watch Dr. Scott Tagawa discuss the future of based on the existing data from the phase III PSMAddition trial for metastatic hormone-sensitive : https://bit.ly/4hv10IU (cc: GU Oncology Now )

Drs. Tagawa, Nizam continue their discussion on PSMAddition, focusing on safety outcomes and long-term implications.

10/28/2025

Dr. Scott Tagawa spoke with OncLive about the phase 3 for patients with prostate specific-membrane antigen ( )-positive metastatic hormone-sensitive that he presented at :

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.